Assignee profile:

Advaxis, Inc.

City:

Princeton, New Jersey

Country:

United States

Published Applications:

31

Last publication date:

2024-04-18

Patent Grants:

17

Last grant date:

2023-07-18

Top Inventors for applications by Advaxis, Inc.

These are the the leading inventors for applications assigned to Advaxis, Inc.:

Recent patent applications by Advaxis, Inc.

Advaxis, Inc. based in Princeton, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-04-18
US20240124540A1
Chemistry; metallurgy

IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF

#2 | 2023-11-09
US20230357781A1
Chemistry; metallurgy

LISTERIA-BASED COMPOSITIONS COMPRISING A PEPTIDE MINIGENE EXPRESSION SYSTEM AND METHODS OF USE THEREOF

#3 | 2021-08-12 ✅ Patent 11,702,664 granted on 2023-07-18
US20210246457A1
Chemistry; metallurgy

Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof

#4 | 2021-08-05
US20210239681A1
Physics

COMPOSITIONS AND METHODS FOR EVALUATING POTENCY OF LISTERIA-BASED IMMUNOTHERAPEUTICS

#5 | 2021-06-17
US20210177955A1
Human necessities

IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF

#6 | 2021-01-07
US20210003558A1
Physics

COMPOSITIONS AND METHODS FOR EVALUATING ATTENUATION AND INFECTIVITY OF LISTERIA STRAINS

#7 | 2020-08-20 ✅ Patent 11,179,339 granted on 2021-11-23
US20200261369A1
Human necessities

Compositions and methods for lyophilization of bacteria or listeria strains

#8 | 2020-03-05 ✅ Patent 11,446,369 granted on 2022-09-20
US20200069785A1
Human necessities

Compositions and methods comprising KLK3 or FOLH1 antigen

#9 | 2020-02-27
US20200061167A1
Human necessities

COMBINATION OF LISTERIA-BASED VACCINE WITH ANTI-CTLA-4 OR ANTI-CD137 ANTIBODIES

#10 | 2019-12-19
US20190381160A1
Human necessities

PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF

#11 | 2019-10-24 ✅ Patent 11,897,927 granted on 2024-02-13
US20190322714A1
Chemistry; metallurgy

Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof

#12 | 2019-08-15
US20190248856A1
Chemistry; metallurgy

Listeria-Based Immunogenic Compositions Comprising Wilms Tumor Protein Antigens And Methods Of Use Thereof

#13 | 2019-08-08
US20190240303A1
Human necessities

RECOMBINANT LISTERIA VACCINE STRAINS AND METHODS OF PRODUCING THE SAME

#14 | 2019-01-31
US20190032064A1
Chemistry; metallurgy

Personalized Delivery Vector-Based Immunotherapy and Uses Thereof

#15 | 2019-01-03 ✅ Patent 10,900,044 granted on 2021-01-26
US20190002891A1
Chemistry; metallurgy

Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof

#16 | 2018-10-25
US20180305702A1
Chemistry; metallurgy

Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment

#17 | 2017-04-20 ✅ Patent 10,143,734 granted on 2018-12-04
US20170106072A1
Human necessities

Biomarker directed multi-target immunotherapy

#18 | 2017-04-13
US20170100469A1
Human necessities

COMPOSITIONS AND METHODS COMPRISING KLK3 OR FOLH1 ANTIGEN

#19 | 2017-02-16 ✅ Patent 10,258,679 granted on 2019-04-16
US20170042996A1
Human necessities

Recombinant vaccine strains and methods of producing the same

#20 | 2016-11-10 ✅ Patent 10,064,898 granted on 2018-09-04
US20160324903A1
Human necessities

Listeria-based adjuvants

#21 | 2016-08-04
US20160220652A1
Human necessities

METHODS OF USING RECOMBINANT LISTERIA VACCINE STRAINS IN DISEASE IMMUNOTHERAPY

#22 | 2016-01-28 ✅ Patent 9,907,849 granted on 2018-03-06
US20160022814A1
Human necessities

Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer

#23 | 2015-11-26 ✅ Patent 9,549,973 granted on 2017-01-24
US20150335721A1
Human necessities

Compositions and methods comprising KLK3 or FOLH1 antigen

#24 | 2015-04-09 ✅ Patent 10,058,599 granted on 2018-08-28
US20150098964A1
Human necessities

Suppressor cell function inhibition following vaccine treatment

#25 | 2014-09-04 ✅ Patent 9,499,602 granted on 2016-11-22
US20140248304A1
Human necessities

Non-hemolytic LLO fusion proteins and methods of utilizing same

#26 | 2014-08-21
US20140234370A1
Human necessities

COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS

#27 | 2014-07-17 ✅ Patent 9,463,227 granted on 2016-10-11
US20140199258A1
Human necessities

Listeria-based adjuvants

#28 | 2012-07-12 ✅ Patent 8,956,621 granted on 2015-02-17
US20120177678A1
Human necessities

Compositions and methods for treatment of cervical dysplasia

#29 | 2012-01-19 ✅ Patent 9,017,660 granted on 2015-04-28
US20120014984A1
Human necessities

Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

#30 | 2011-06-16 ✅ Patent 9,084,747 granted on 2015-07-21
US20110142791A1
Human necessities

Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors

#31 | 2007-11-01 ✅ Patent 9,012,141 granted on 2015-04-21
US20070253976A1
Human necessities

Compositions and methods comprising KLK3 of FOLH1 antigen

Also check out ADVAXIS, INC.'s (Princeton, United States) applicant profile with 15 patent applications submitted.

AssigneeID:

75445 ⎘